Lexchin Joel
Professor Emeritus, School of Health Policy and Management, York University; Emergency Physician, University Health Network; Associate Professor, Department of Family and Community Medicine, University of Toronto, Toronto, ON.
Healthc Policy. 2017 Aug;13(1):10-16. doi: 10.12927/hcpol.2017.25195.
The interest of the pharmaceutical industry is in achieving a profit for its shareholders while the interest of the Canadian government should be in protecting public health. However, over the course of the past few decades the actions of the Canadian government have been tilted in favour of industry in two areas. The first is in the relationship between industry and Health Canada and is manifested in the regulation of clinical trials, the drug approval system, drug safety and promotion. The second is in economic policy as it applies to policies about patent protection, the price of medications and measures taken to incentivize research and development. The problems in the relationship are structural and will only be solved through systemic changes.
制药行业的利益在于为其股东实现利润，而加拿大政府的利益则应在于保护公众健康。然而，在过去几十年中，加拿大政府的行动在两个领域向行业倾斜。第一个领域是行业与加拿大卫生部之间的关系，体现在临床试验监管、药品审批系统、药品安全和推广方面。第二个领域是经济政策，涉及专利保护政策、药品价格以及为激励研发而采取的措施。这种关系中的问题是结构性的，只有通过系统性变革才能解决。
